Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Enkelt stigende dosis undersøgelse af HEC-151 injektion

24. september 2026 opdateret af: Sunshine Lake Pharma Co., Ltd.

En I-fase klinisk undersøgelse, der evaluerer sikkerheden, tolerabiliteten og de farmakokinetiske/farmakodynamiske egenskaber af en enkelt dosis HEC-151-injektion hos raske kinesiske deltagere i en enkeltcenter, randomiseret, placebo (enkeltblind) og positiv kontrol (åben) undersøgelse

Evaluate the safety, tolerability, PK/PD and immunogenicity characteristics of a single subcutaneous HEC-151 Injection solution in healthy participants

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

81

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Chengyong Tang, Doctor
  • Telefonnummer: +8618983286980
  • E-mail: 17235387@qq.com

Studiesteder

    • Bishan
      • Chongqing, Bishan, Kina, 402760
        • Rekruttering
        • No. 9, Shuangxing Avenue,, Bishan
        • Kontakt:
          • Chengyong Tang, Doctor
          • Telefonnummer: 8618983286980
          • E-mail: 17235387@qq.com
    • Chongqing Municipality
      • Bishan, Chongqing Municipality, Kina, 402760
        • Ikke rekrutterer endnu
        • No. 9, Shuangxing Avenue,
        • Kontakt:
          • Chengyong Tang, Doctor
          • Telefonnummer: +8618983286980
          • E-mail: 17235387@qq.com

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 45 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Han

Beskrivelse

Inclusion Criteria:

  1. Voluntarily participate in the trial and sign the informed consent form, understanding and abiding by the research procedures;
  2. When signing the informed consent form, men aged 18-45 years old (including the boundary value) are eligible;
  3. During the screening process, male subjects with a body weight of ≥ 50 kg and a body mass index (BMI) of ≥ 19.0 and ≤ 24.0 kg/m2 are included;
  4. Normal glucose tolerance [3.9 mmol/L < fasting blood glucose (FPG) < 6.1 mmol/L, and 2-hour post-glucose tolerance test (OGTT) blood glucose after sugar intake < 7.8 mmol/L];
  5. Normal results of insulin release test (IRT), or abnormal results but judged by the researcher to have no clinical significance;
  6. Glycated hemoglobin (HbA1c) < 5.7%;
  7. During the study period, there are no plans for reproduction, sperm collection, or sperm donation, and are willing to take effective contraceptive measures throughout the study period until 3 months after the administration of the investigational drug.

Exclusion Criteria:

  1. Participants with abnormal medical histories or surgical histories judged clinically significant by the researchers, or currently suffering from any diseases in the endocrine system, blood system, cardiovascular system, respiratory system, digestive system, urinary system, immune system, nervous system, etc. that are judged clinically significant by the researchers, or any other diseases or physiological conditions that can significantly affect the absorption, distribution, metabolism or excretion of the drugs;
  2. Participants who have a known severe allergic history or are allergic to the test drugs and any of their components;
  3. Participants who had severe trauma or undergone surgery within 90 days before the screening, or plan to undergo major surgery during the study;
  4. Participants who have a history of hypoglycemia or hyperglycemia within 90 days before the screening, or have a family history of diabetes (first-degree direct relatives);
  5. Participants who have donated blood or suffered significant blood loss (≥ 400 mL) within 90 days before the screening, or plan to donate blood during the study;
  6. Participants who have acute diseases or concurrent medication use from the signing of the informed consent form to the first administration of the drug;
  7. Participants whose vital signs, physical examination, laboratory tests, electrocardiogram, chest X-ray examination, etc. results are abnormal and judged by the researchers to have clinical significance;
  8. Participants whose test results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV), combined human immunodeficiency virus antigen antibody (HIV), or syphilis spirochete antibody (TP) are positive;
  9. Participants who have a history of drug abuse or drug use, or whose urine drug screening is positive before the screening;
  10. Participants who have used any prescription drugs, Chinese herbal medicines, over-the-counter drugs, health supplements (except for regular supplementary vitamins and calcium) within 30 days before the screening;
  11. Participants who have participated in any clinical research of drugs or devices (defined as receiving the test drugs or devices) within 90 days before the screening;
  12. Participants who have received any vaccine within 30 days before the screening, or plan to receive any type of vaccine during the study;
  13. Participants who smoke more than 5 cigarettes per day within 90 days before the screening, or cannot comply with the smoking prohibition rule during the study;
  14. Participants who frequently drink alcohol, that is, consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine), or have a positive alcohol breath test; or who cannot comply with the alcohol prohibition rule during the study;
  15. Participants who consume excessive tea, coffee and/or caffeine-rich beverages (more than 8 cups, 1 cup ≈ 250 mL) or food (such as chocolate) every day within 90 days before the screening, or during the study;
  16. Participants who have used special diets (including dragon fruit, mango, pomelo, etc.) and/or xanthine diet (salmon, sardines, liver, kidney, etc.) or have other factors affecting drug absorption, distribution, metabolism, and excretion before the signing of the informed consent form to the use of the test drugs, or who cannot comply with the prohibition of eating during the study;
  17. Participants who have had significant changes in diet or exercise habits within 90 days before the screening, or have engaged in intense exercise before the signing of the informed consent form to the use of the test drugs, or cannot stop during the study;
  18. Participants who have difficulty in venous blood collection, or cannot tolerate venipuncture, or have a history of fainting or hematemesis;
  19. Participants who, in the researcher's opinion, have other factors that are not suitable for participating in this study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: HEC-151 Injection

The participants received an abdominal subcutaneous HEC-151 Injection in the morning of Day 1.

Subcutaneous injection in the abdominal area

Aktiv komparator: Insulin Degludec

The participants received an abdominal subcutaneous injection of Insulin Degludec in the morning of Day 1.

Subcutaneous injection in the abdominal area

Placebo komparator: Placebo

The participants received an abdominal subcutaneous Injection of placebo in the morning of Day 1.

Subcutaneous injection in the abdominal area

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Adverse event
Tidsramme: From Day1 to Day36

Frequency, type and severity of adverse events/serious adverse events.

From Day1 to Day36
Electrocardiogram parameter(Heart rate)
Tidsramme: From Day1 to Day36

Evaluation the heart rate of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Electrocardiogram parameter(PR interval)
Tidsramme: From Day1 to Day36

Evaluation the PR interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Electrocardiogram parameter(QTcF interval)
Tidsramme: From Day1 to Day36

Evaluation the QTcF interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Electrocardiogram parameter(QRS interval)
Tidsramme: From Day1 to Day36

Evaluation the QRS interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Vital signs parameter(Body temperature)
Tidsramme: From Day1 to Day36

Evaluation the body temperature of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Vital signs parameter(Blood pressure)
Tidsramme: From Day1 to Day36

Evaluation the blood pressure of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Vital signs parameter(Pulse)
Tidsramme: From Day1 to Day36

Evaluation the pulse of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Vital signs parameter(Respiration)
Tidsramme: From Day1 to Day36

Evaluation the respiration of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cmax
Tidsramme: From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
AUC0-t
Tidsramme: From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
Tmax
Tidsramme: From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
T1/2
Tidsramme: From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
CL/F
Tidsramme: From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
GIRmax
Tidsramme: From Day1 to Day36

Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
tGIRmax
Tidsramme: From Day1 to Day36

Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
AUCGIR
Tidsramme: From Day1 to Day36

Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
ADA(Anti-Drug Antibody)
Tidsramme: From Day1 to Day36

Evaluate the Immunogenic characteristics of HEC-151 Injection in healthy participants.

From Day1 to Day36

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

24. februar 2026

Primær færdiggørelse (Anslået)

31. december 2026

Studieafslutning (Anslået)

31. januar 2027

Datoer for studieregistrering

Først indsendt

14. januar 2026

Først indsendt, der opfyldte QC-kriterier

21. januar 2026

Først opslået (Faktiske)

29. januar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

24. september 2026

Sidst verificeret

1. januar 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • HEC-151-DM-101

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .